Pyxis Oncology (NASDAQ:PYXS) Trading 1.5% Higher

Pyxis Oncology, Inc. (NASDAQ:PYXSGet Rating) shares rose 1.5% on Thursday . The company traded as high as $2.75 and last traded at $2.72. Approximately 24,774 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 154,089 shares. The stock had previously closed at $2.68.

Pyxis Oncology Stock Performance

The company’s 50 day moving average is $2.56 and its 200 day moving average is $4.15.

Pyxis Oncology (NASDAQ:PYXSGet Rating) last announced its quarterly earnings results on Friday, May 13th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.35). Analysts predict that Pyxis Oncology, Inc. will post -3.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of PYXS. New York State Common Retirement Fund acquired a new stake in Pyxis Oncology during the 4th quarter worth $69,000. Davidson Kempner Capital Management LP acquired a new position in Pyxis Oncology in the fourth quarter valued at $109,000. Sandia Investment Management LP acquired a new position in Pyxis Oncology in the fourth quarter valued at $110,000. Bank of New York Mellon Corp increased its stake in Pyxis Oncology by 69.0% in the first quarter. Bank of New York Mellon Corp now owns 32,589 shares of the company’s stock valued at $132,000 after purchasing an additional 13,305 shares during the period. Finally, Ghisallo Capital Management LLC acquired a new position in Pyxis Oncology in the fourth quarter valued at $329,000. 61.30% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

(Get Rating)

Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

Featured Articles

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.